19 Years old male with ST elevation myocardial infarction as an initial manifestation of primary antiphospoholipid syndrome
Journal: International Journal of Vascular Surgery and Medicine (Vol.3, No. 3)Publication Date: 2017-12-29
Authors : Lana Maričić; Roberta Višević;
Page : 040-042
Keywords : Antiphospholipid syndrome; Antiphospholipid antibodies; Acute myocardial infarction;
Abstract
Antiphospholipid antibody syndrome (APS) is a systemic, autoimmune, acquired disorder characterized by venous and/or arterial thrombosis and/or pregnancy morbidities [1]. Although detectable at 1-5% of asymptomatic subjects, persistent antiphospholipid antibodies (aPL) are significantly associated with recurrent arterial/venous thrombosis and pregnancy morbidity [2]. The 2006 International consensus Statement on an Update of the classification criteria recognize those antiphospholipid antibodies (aPLs): lupus anticoagulant (LA), anticardiolipin antibodies (ACA) IgM or IgG and antibody to 2 glycoprotein 1 (-2-GP I) [3]. Those should be confirmed at least two occasions, 12 weeks apart [1]. Primary APS has generally been defined as the presence of aPL in patients with idiopathic thrombosis, but no evidence of autoimmune disease or other inciting factor, such as infection, malignancy, hemodialysis or drug-induced APL.
Other Latest Articles
- REFLECTION OF PROTAGONIST’S WORLDVIEW IN A CONTEMPORARY ARABIC NOVEL A CASE STUDY OF LATIN QUARTER (AL-HAYY AL-LATINI)
- Diagnosis and indications for revascularization in Takayasu’s Arteritis: Report of two cases and literature review
- Iliac Vein Injury during Total Hip Replacement: A Rare Iatrogenic Complication and its Successful Surgical Treatment
- Acute on Chronic Renal Failure has Worse Postoperative Outcomes than End-Stage Renal Disease Following Cardiac Surgery
- Comparison of MELD and Child- Pugh Score for the Prediction of Survival in Portal Hypertension Undergoing Transjugular Intrahepatic Portosystemic Shunt
Last modified: 2018-09-14 14:59:01